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Abstract  
Citrulline displays a highly specific metabolism. Citrulline bypasses the splanchnic extraction; 
it is neither used by the intestine nor taken up by the liver. Thus the administration of 
citrulline may be utilized to deliver nitrogen making it available for the protein homeostasis in 
peripheral tissue and as an arginine precursor synthesized de novo in the kidneys, in 
endothelial and immune cells. A recent work showed that citrulline is efficiently transported 
across the intestinal luminal membrane, using a set of transporters belonging to systems B
0,+
, 
L, b
0,+
. Several pharmacokinetic studies confirm that citrulline is efficiently absorbed when 
orally administered. Oral citrulline could be used either as a method to deliver arginine to the 
systemic circulation or as a protein anabolic agent in specific clinical situations: recent data 
suggest that citrulline, while not a component of proteins, stimulates protein synthesis in 
skeletal muscle through the mTOR signalling pathway. Hence, citrulline could play a pivotal 
role in maintaining protein homeostasis and is a promising pharmaconutrient in nutritional 
strategies in malnourished patients, especially in aging and sarcopenia. 
Key words:  citrulline, metabolism, transport, pharmacokinetics, arginine 
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1. Introduction 
Citrulline was firstly identified and isolated from the juice of watermelon, Citrullus vulgaris 
(1). This amino acid attracted relatively little interest until recently because it is a non protein 
amino acid and considered solely as an intermediate metabolite in ureagenesis (2, 3). 
However, in the last decade interest about citrulline has risen substantially because of its very 
specific metabolism.  
Since citrulline is almost exclusively synthesized by the intestine, plasma citrulline has been 
identified as a biomarker of functional small bowel enterocyte mass (for recent reviews see 4, 
5). In addition, as kidney is the main organ that metabolizes citrulline into arginine, renal 
failure is associated with an impairment of citrulline metabolism. The increase in plasma 
citrulline has been reported to be a potential marker of renal function (6). These features 
highlight the major role of intestine and kidneys in citrulline production and disposal 
respectively. 
As it is a precursor of arginine, citrulline is also being investigated as a supplement from 
which arginine can be synthesized. In addition, arginine can be recycled from citrulline in 
some cells and this is of major importance in the so-called nitric oxide (NO) cycle. Hence 
citrulline can act as an arginine precursor for NO synthesis (7) and plays an important role in 
the metabolism and regulation of NO (8). Therefore, its administration may constitute a 
therapeutic strategy for controlling NO metabolism disorders and improving cardiovascular 
function. Citrulline supplementation should be considered for use in all circumstances or 
disease states in which arginine has beneficial effects and/or where arginine supplementation 
may be considered as harmful (9). Moreover, aging is associated with high splanchnic 
sequestration of amino acids and sarcopenia (10). Citrulline escapes splanchnic extraction and 
can stimulate muscle protein synthesis (11). Thus administering citrulline is a tool to deliver 
adequate amounts of nitrogen to peripheral tissues, including the muscle, in elderly. 
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Therefore, citrulline administration has potential beneficial effects in different situations. In 
this review paper, we report experimental data of pharmacokinetic studies and clinical trials 
involving oral administration of citrulline as an alternative to arginine. As citrulline 
bioavailability is dependent on its intestinal absorption and amino acid transport systems may 
regulate substrate availability for citrulline-requiring enzymes in the intestine, a brief 
description of citrulline amino acid transport systems will be done.  
 
2. Metabolism of citrulline 
 
2.1. Citrulline transport studies in intestinal models 
 
In the rat intestine, citrulline absorption seems to be optimal between the median and lower 
ileum (12). In addition, there is no evidence for an increased or decreased uptake of L-
citrulline by enterocytes under low or high protein or L-citrulline intake (8). 
While citrulline transport in several cell types is well characterised (Table 1), currently 
transport mechanism of L-citrulline in the intestine is poorly documented. There are only two 
reports describing a concentration gradient transport across the everted sacs of the rat intestine 
(13) and an active transport by a neutral amino acid transport system in the hamster intestine 
(14). It was also showed in everted sacs of the small intestine that citrulline transport is 
mediated by a carrier-mediated active transport (12). Competition studies revealed the 
implication of NBB system. This system corresponds to the system B
0
 (15). L-citrulline could 
also be transported by a system analogous to system ASC (12).  
In Caco-2 cells, a model for intestinal uptake studies, we have characterized kinetics of 
citrulline uptake (16). At the apical side, citrulline uptake involved a Na
+
- dependent 
transporter (System B
0,+
) and a Na
+
- independent saturable transport including systems L and 
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b
0,+ 
and no saturable diffusion. These transport systems take up citrulline from the lumen with 
comparable activities (table 1). It can be hypothesized that this large spectrum of transport 
systems compensates for the low content of citrulline in food, which may be important given 
the key role of citrulline in arginine de novo synthesis (16).  
Citrulline transport has also been characterized in several other cell types: macrophages (17), 
rat aortic smooth muscle cells (18), neural cell cultures (19) and bovine aortic endothelial 
cells (20) (Table 1).  
 
2.2. Intestinal metabolism of citrulline 
Intestinal citrulline production originates mainly from the proximal small bowel and probably 
from the middle and upper parts of intestinal villi (4). 
Glutamine is generally considered as the major precursor of citrulline in the intestine (7). 
Citrulline is one of the end products of glutamine metabolism accounting for 27.6 % of 
metabolized glutamine (21). The synthesis of citrulline from glutamine involves five 
mitochondrial enzymes: phosphate-dependent glutaminase (PDG), pyrroline-5-carboxylate 
synthase (P5CS), ornithine aminotransferase (OAT), OCT (ornithine carbamoyltransferase) 
and CPSI (carbamoyl phosphate synthetase I) (22). Key regulation enzymes are OAT and 
P5CS which are unique to small intestinal enterocytes (23). This metabolic pathway is 
summarized in figure 1. 
Besides, glutamine and some other amino acids can contribute to the intestinal production of 
citrulline. Indeed, citrulline can be synthesized from arginine because enterocytes possess the 
enzyme arginase which transforms arginine into ornithine (24). Ornithine is then converted 
into citrulline via OCT. Whether glutamine or arginine is the major precursor of citrulline is 
now controversial (25, 26). 
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2.3. Whole body inter-organ exchanges and catabolism 
Following release from enterocyte, citrulline passes through the liver without major 
metabolism and reaches the systemic circulation. The liver does not contribute significantly to 
circulating citrulline levels (21). Human liver might be capable of taking up a substantial 
amount of intestinal derived citrulline and thus limiting the amount of citrulline reaching the 
kidney (27). However in that study, the subjects were studied per-operatively for cancer. It 
cannot be excluded that liver bearing cancer expresses citrulline transporters which do not 
exist in normal liver. 
The kidney is the major consumer of circulating citrulline. It takes up about 1.5 g citrulline 
per day from the blood (28). Approximately 83% of the citrulline released by the gut is 
metabolized within the kidney, and this represents 35% of circulating citrulline (21). 75 % of 
the citrulline extracted from the blood is converted stochiometrically into arginine through a 
partial urea cycle by argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL) 
(23, 29). Synthesized arginine is released into the renal vein and then to systemic blood 
circulation (28). Citrulline converted by the kidney is enough to sustain whole body arginine 
requirements. Arginine synthesized from citrulline represents 60% of the de novo arginine 
synthesis in the organism, but only 5 to 15% of circulating arginine (30).  
3. Pharmacokinetics of citrulline 
Mandel et al. (1) studied the response of plasma citrulline and arginine to ingestion of 
watermelon in healthy volunteers. A one-time intake of watermelon increased plasma 
concentrations of citrulline and arginine when measured immediately after ingestion (Table 2) 
and then declined to baseline concentrations at 8 h post watermelon ingestion. The study is 
limited by uncertainty as to the actual amount of citrulline ingested, but the mean citrulline 
intake was likely around 7 g. Collins et al.(31) investigated whether watermelon juice 
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consumption increases fasting concentrations of plasma arginine, ornithine and citrulline in 
healthy humans. In contrast to Mandel et al. (1), they used long-term feeding with watermelon 
(31). Three weeks of daily ingestion of 6 cups of watermelon juice elevated plasma arginine 
and ornithine concentrations (table 2). No significant changes in fasting plasma citrulline were 
found. This is due to the high turnover rate of arginine and citrulline.  
In conclusion, dietary supplementation with citrulline is an effective alternative to oral 
administration of arginine. Hence watermelon may have important implications for preventing 
and treating diseases involving arginine deficiency (31). However, the use of large volume of 
watermelon juice raises the question of good compliance in the context of long term feeding. 
In healthy volunteers, Moinard et al. (32) performed a dose-ranging study of citrulline oral 
administration. After citrulline load, plasma citrulline and arginine concentrations increased 
proportionally to citrulline load rapidly and massively and returned to baseline after 5-8 h. 
However, at the highest dose (15 g), arginine production was not related to the dose 
administered, suggesting that citrulline to arginine conversion in the kidney may be limiting 
and that saturation begins to occur at around this dose of citrulline. Therefore, Moinard et al. 
(32) suggest that a 10 g dose should be the most appropriate for use in clinical practice. 
Plasma concentrations of amino acids other than ornithine and arginine are not affected by 
citrulline supplementation (31, 32). This means that citrulline is a compartmentalized amino 
acid performing a specific job in terms of arginine metabolism (32).  
Rougé et al. (33) also found that oral administration of citrulline can be used to enhance 
systemic citrulline and arginine availability and nitrogen balance. Citrulline is highly 
bioavailable, since systemic citrulline rose dramatically whereas urinary citrulline loss was 
minimal (32, 33).  
Moreover, Kuhn et al. (34) observed that oral citrulline is more effective than arginine itself 
in elevating circulating arginine levels (table 2) and speculate that it may be more effective in 
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raising nitric oxide levels in patients with pulmonary hypertension. This observation is 
confirmed by the study of Schwedhelm et al. (35). Pharmacokinetic parameters were 
calculated after 1 week of oral supplementation of six different dosing regimens of placebo, 
citrulline and arginine (Table 2). Oral citrulline supplementation raised plasma arginine 
concentration and increased NO-dependent signalling in a dose dependent manner. Besides, at 
the dose of 3 g, citrulline was more efficient in increasing Cmax, Cmin and AUC over baseline 
placebo than arginine itself.  
A recent study (36) compared the pharmacokinetics of citrulline, arginine and glutamine 
supplied orally, in catabolic conditions in rats. Endotoxemia considerably decreased citrulline 
bioavailability, whereas it did not affect arginine and glutamine pharmacokinetics. These 
results could have important clinical implications. However, if the target of citrulline 
supplementation is to use it as an arginine precursor, citrulline remained a better arginine 
precursor than arginine itself in this pathological condition (36). However, if the target is the 
specific anabolic properties of citrulline (see below), it may certainly be better to provide 
citrulline by the parenteral route. 
Finally, the rapid disappearance of citrulline from the blood may be a disadvantage if we 
consider that high citrulline plasma level may trigger its action. For this purpose, galenic 
formulations have been established to sustain its plasma level (37). 
 
4. Perspectives for therapeutic use of citrulline 
4.1. In malnutrition state 
4.1.1. Malnutrition associated to intestinal failure 
Citrulline is lowered after a large intestinal resection leading to intestinal failure (38), in 
villous atrophy (39) or in HIV enteropathy (40). Recent papers discuss the interest of 
citrulline concentration as an indicator of acute intestinal failure in critically ill patients (41) 
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or as marker of bowel adaptation in children with short bowel syndrome (42). Since citrulline 
and subsequently arginine concentrations are decreased in these situations, arginine 
supplementation seems logical, arginine becoming essential (43). Nevertheless, arginine 
undergoes significant liver uptake and its metabolism (e.g. into NO) raises concerns over 
whether arginine supplementation may potentially be unsafe (9). Last but not least, arginine is 
relatively badly absorbed by the intestine, leading to intestinal discomfort and diarrhea when 
given at high dosage (44). Conversely, citrulline has very high bioavailability (45).  
In experimental intestinal resection, one study has supplemented citrulline instead of arginine 
by enteral route (43) whereas a second study used citrulline by parenteral route (46). In the 
first study, rats were assigned to four groups: citrulline, arginine, controls and shams. The 
latter underwent transection while the three other groups underwent 80% resection of the 
small intestine. Plasma and muscle arginine concentrations were higher in the citrulline group 
than in the other groups. Nitrogen balance was preserved in citrulline-treated resected rats but 
not in arginine-supplemented rats. In the parenteral study (46), rats were assigned to four 
groups as in the previous study. Both citrulline and arginine increased mucosal protein 
content in the ileum. However, only citrulline prevented extensor digitorum longus atrophy. 
In addition, arginine worsened nitrogen balance whereas citrulline was unable to improve it, 
in contrast with enteral citrulline supplementation (43). Only citrulline was able to prevent 
muscle atrophy. This was achieved independently of any noticeable effect on the gut, since 
citrulline and arginine shared the same positive effect on mucosal ileal protein content. To 
date there is no data on the potential effects of citrulline on intestinal adaptation. 
 
  4.1.2. Aging and sarcopenia 
Aging is associated with a progressive loss of muscle mass and function (47). In elderly, 
sarcopenia is associated to a reduced post prandial rate of muscle protein synthesis (48). This 
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may be due to a higher splanchnic extraction in the elderly (49) which implies that fewer 
amino acids reach the systemic circulation (50). Increasing the overall availability of amino 
acids can enhance protein synthesis in skeletal muscle by increasing the activities of positive 
regulators of translation initiation factors (47). Only one amino acid (i.e. leucine) was firmly 
proven to have a direct effect on muscle protein synthesis (51). This amino acid can activate 
several intracellular signals involved with initiating translation, the mammalian target of 
rapamycin (mTOR) signaling pathway, which includes 70-kda ribosomal protein S6 kinase 
(S6K1) and eukaryotic initiation factor 4E binding protein-1 (4E-BP1) (47). Recently it has 
been shown that dietary arginine supplementation increased mTOR signaling activity in 
skeletal muscle of neonatal pigs (52). The arginine treatment enhanced the formation of the 
active eIF4E
.
eIF4G complex and reduced the amount of the inactive 4E-BP1
.
eIF4E complex 
in muscle (52). 
Citrulline supplementation led to increase in muscle protein content as well as muscle protein 
synthesis in elderly malnourished rats (11). It can directly stimulate protein synthesis 
particularly in the myofibrillar and sarcoplasmic protein synthesis (53). This amino acid 
activates the phosphorylation of proteins in the mTOR signaling pathway. Further study (54) 
using the same model support the idea that citrulline action is modulating protein synthesis 
through mTOR since this effect was counteracted when muscles were incubated in presence 
of rapamycin. 
Recently, Faure et al. (55) demonstrated that muscle mass and motor activity significantly 
increased during refeeding of malnourished aged rats with citrulline. This study demonstrates 
the ability of citrulline to modulate muscle function. Of major interest, a recent study (56) 
indicates that orally administered citrulline increases muscle protein synthesis in healthy 
volunteers fed a hypoprotein diet, compared to isonitrogenous control. 
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4.2. Cardiovascular diseases 
In most studies, citrulline was investigated as a supplement from which arginine can be 
synthesized or as a NO precursor. In children undergoing surgical procedures for congenital 
heart lesions, oral citrulline supplements safely increased plasma citrulline and arginine 
concentrations compared with placebo and improved NO production (57). The arginine level 
was maintained in these patients, whereas it decreased in patients receiving the placebo. 
Increased plasma citrulline concentrations were associated with a decreased risk of 
postoperative pulmonary hypertension.  
In sickle cell disease, citrulline had also a systemic vasodilator antihypertensive effect (58). 
Administered orally, citrulline improved cardiac performance with exercise and sense of well-
being. It reduced total leukocyte counts and neutrophil counts (58).  
 
4.3. Safety issues 
Citrulline is generally recognized as safe for oral use (8). At the opposite of arginine or 
ornithine that induces gastrointestinal side effects at high dosage (i.e. > 10 g in one bolus) 
(44), citrulline is well tolerated (31, 32, 35, 57, 58). This could be explained by rapid 
saturation of the intestinal absorption of arginine and ornithine which induce osmotic 
diarrhoea at high loads (32, 44). This difference between these amino acids suggests that 
intestinal absorption of citrulline is not a limiting step in citrulline bioavailability, even at high 
citrulline loads.  
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5. Conclusion  
The intestinal epithelium plays a central role in maintaining citrulline homeostasis by 
systemic providing citrulline. Citrulline is easily absorbed by the gut with a broad set of 
transporters that can carry it from the intestinal lumen in the enterocyte. This is confirmed by 
the result of pharmacokinetic studies. The major finding of these studies is that oral 
administration of L-citrulline efficiently increases L-arginine plasma concentrations. 
Moreover, giving citrulline is more efficient to provide systemic arginine than giving arginine 
itself, likely because it bypasses metabolism in the liver and it is not a substrate for arginase. 
Therefore, the use of citrulline as a pharmaconutrient is a promising treatment in diseases 
involving arginine deficiency. Another promising field of research for citrulline is its role in 
protein synthesis.  
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Figure 1: Interorgan metabolism of citrulline and related amino acids.  
GLNase, Glutaminase ; OAT, ornithine aminotransferase ; OCT, ornithine 
carbamoytransferase ; ARGase, arginase ; ARG, arginine; CIT, citrulline ; ORN, 
ornithine ;.GLN, glutamine; GLU, glutamate ; ASS+ASL, argininosuccinate synthetase + lyase 
Adapted from Crenn et al. (5). Reproduced with permission. 
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Table 1: Characteristics of citrulline transport across cellular membranes 
                
Cell type  Km (mM) Vmax (nmol .min
-1
) Amino acid transport system Reference 
Caco-2 Cells 
0.46 ± 0.07 3.58  ± 0.39 B
0,+
 
16 
0.67 ± 0.1 2.16  ± 0.23 L and b
0,+
 
Rat intestinal everted sacs  4.1 ± 0.9 0.62 ± 0.06* ASC or B
0
 12 
Aortic endothelial cell   Common transport system with arginine 20 
Aortic smooth muscle cell 1.6 ± 0.2 5.9 ± 0.6 L and N 18 
Astroglial cell  1.1 ± 0.1 14.7 ± 0.9 
L 
19 
 
Glial cells 3.4  ± 0.2 25.6 ± 1.4 
Microglial cell 1.2 ± 0.4 31 ± 0.2 
Macrophage 0.4 ± 0.1 26.5  ± 8.7 
Macrophage 0.16 ± 0. 02 32 ± 1 Neutral AA transport system with a broad specificity 17 
 
Vmax values are for 1mg of protein, except when marked with a star where values are for 1mg of wet tissue 
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Table 2: Pharmacokinetic studies of citrulline 
Study Patients Dosage
1
 Plasma concentration achieved, µmol/l Reference 
Randomized study 10 healthy volunteers 0.18 g/kg/d 
- Cit: increase of 448 ± 92 % (from 39 ± 4 to 225 ± 44)  
- Arg: increase of 92 ± 57 %  (from 134 ± 33 to 247 ±62)  
- Increase in urine and RBC Cit  
- No change in urinary Arg, nor plasma urea, urinary urea 
nitrogen excretion thus enhanced nitrogen balance 
33 
Double-blind randomized 
placebo-controlled  
cross over study 
20 healthy volunteers 
Cit : 0.75, 1.5 and 3 g twice daily 
Arg: immediate release (IR) 1g tid, sustained 
release (SR) 1.6 twice daily for 1 week 
After load of 3 g Cit  
- Cit : Tmax = 0.7 ± 0.1 h, Cmax = 846 ± 45µmol/l 
- Arg : Tmax = 1.4 ± 0.1h, Cmax = 149 ±42µmol/l 
35 
Simple-blind  
cross over study 
8 healthy adult 2, 5, 10 or 15 g of Cit 
After ingestion of 10 g of Cit  
- Cit Tmax = 0.72 ± 0.08 h, Cmax = 2756 ± 70µmol/l 
- Arg Tmax = 1.67 ± 0.05h, Cmax = 280 ±1043µmol/l 
32 
Cross-over pharmacokinetic 
study 
7 normal volunteers  
 
Single equimolar oral dose of arg and cit 3.8 
g/m2 body surface area 
After oral Cit load: 
- Cit: increase 40 fold (from 31 ± 3 to 1275 ± 95)  
- Arg: increase of 227 % (from 72 ± 5 to 236 ± 5)   
- Arg: AUC = 1440 ± 196µMxhrs 
After oral Arg load: 
 - Arg: increase of 90% (from 107 ± 19 to 229 ± 33)  
- Arg : AUC = 476 ± 259 µMxhrs 
 
34 
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Study Patients Dosage
1
 Plasma concentration achieved, µmol/l Reference 
Randomized placebo -
controlled trial 
 
40 children undergoing surgery 
to correct congenital heart 
lesions 
Cit 1.9 g/m2/dose x 5 
Total dose of 9.5g /m2 
12h postoperative 
Cit : 37 (18-83) vs 20 ± (15-29) (placebo) 
Arg : 36 ± 24 vs 23 ± 13  
57 and 85% increases in mean plasma levels of Arg and 
Cit, respectively 
57 
Pilot phase II clinical trial 
5 sickle cell disease patients 
(ages10-18) 
0.09 to 0.13 g/kg twice daily for 4 weeks Increase of 65% (from 77 ± 9.1 to 127 ± 18) in plasma Arg 58 
Pharmacokinetic study after 
watermelon ingestion  
6 healthy adults 
3.3 kg wet weight of red fruit of ripe 
watermelon 
- Cit: increase from 22 µmol/L to 593 µmol/L (range 386 - 
1069) 1h after ingestion 
- Arg: increase from 65 µmol/L to 199 µmol/L (range 128 - 
251) 2h after ingestion 
 
1 
Pharmacokinetic study after 
watermelon ingestion 
 23 healthy adults 
780 g (i.e. 1 g Cit), 1560 g (i.e. 2 g Cit) 
watermelon juice for 3 weeks 
- Low ingestion of watermelon juice:  
increase of 12 %  in plasma Arg 
- High ingestion of watermelon juice:  
increase of  22 % in plasma Arg , 18% in plasma Orn. 
31 
1
Citrulline or otherwise stated 
